Merck’s Hepatitis B Vaccine Shortage Linked to Reduced Deaths In Babies

In the summer of 2017, a malware virus mainly affecting the Ukraine, found its way onto the mainframe computer systems of Merck wreaking havoc for the company. According to the Wall Street Journal, the incident cost the pharmaceutical giant $670 million to remediate, but more importantly, it caused disruption to the production of two of Merck’s pediatric vaccines: Gardasil 9 (Human Papillomavirus) and Recombivax (Hepatitis B virus), vaccines to help prevent sexually transmitted infections. During the crisis, Merck borrowed from a CDC vaccine stockpile, in order to meet supply commitments for Gardasil 9. However, that was not the case with Recombivax, the Hepatitis B vaccine given to all babies beginning the first day of life. There is growing concern among some scientists about the aluminum adjuvant load in vaccines and its effects on the neurological health of children. Researchers are particularly concerned with Merck’s highly immunogenic adjuvant, Amorphous Aluminum Hydroxyphosphate Sulphate (AAHS). Gardasil and Recombivax are the only vaccines licensed to contain AAHS. We now have more than a year’s worth of data to examine since the attack in 2017 when Engerix-B was introduced. On average there were 29 deaths reported annually for fifteen years prior to the attack (2003 to 2017). In 2018 there were only 6 reported (to end of November 2018). Two of those deaths followed Recombivax.

Are Vaccine Manufacturers Concealing Deaths Caused by Vaccines by Manipulating Post-marketing Data?

National and international health agencies such as the Centers for Disease Control and Prevention (CDC), the European Medicines Agency (EMA) and the World Health Organization (WHO) routinely and emphatically claim that serious adverse events following vaccination are rare. Nowhere is officialdom’s minimization of vaccine risks more apparent than in these agencies’ position on vaccine-related deaths. The WHO, for example, states that “so few deaths can plausibly be attributed to vaccines that it is hard to assess the risk statistically.” Nevertheless, once regulators have deemed that a given vaccine is safe enough to be licensed and widely marketed, vaccine manufacturers are supposed to do just that—that is, continue to statistically assess a vaccine’s risks, including the risk of death—and regulators are supposed to carefully review the postlicensure data that pharmaceutical companies submit. A 2017 commentary by India-based physicians Jacob Puliyel and C. Sathyamala in the Indian Journal of Medical Ethics describes a shocking dereliction of duty on the part of regulators who were presented with vaccine data carefully tailored to obscure serious risks. Tackling concerns about infant deaths that have occurred following hexavalent vaccination in several European countries, the authors of the commentary show that GlaxoSmithKline (GSK) neglected to report to regulatory authorities that there was a statistically significant increased risk of sudden infant death in the four days after administration of its hexavalent vaccine—and the regulatory agency in question (the EMA) ignored the omission and accepted GSK’s apparently whitewashed data at face value.

GlaxoSmithKline Found Guilty in Deaths of 14 Babies in Vaccine Trials in Argentina

GlaxoSmithKline Argentina Laboratories Company was fined 400,000 pesos by Judge Marcelo Aguinsky following a report issued by the National Administration of Medicine, Food and Technology (ANMAT in Spanish) for irregularities during lab vaccine trials conducted between 2007 and 2008 that allegedly killed 14 babies. Likewise, two doctors -HĂ©ctor Abate, and Miguel Tregnaghi- were fined 300,000 pesos each for irregularities during the studies. The charges included experimenting with human beings as well falsifying parental authorizations so babies could participate in the vaccine-trials conducted by the laboratory from 2007 to 2008.

Glaxo to Stop Paying Doctors for Drug Promotion

Drug giant GlaxoSmithKline has announced it will no longer pay health care professionals to promote its products or the diseases they treat to “audiences who can prescribe or influence prescribing.” Glaxo also plans to stop compensating its sales representatives based on the number of prescriptions that doctors write. Some experts believe the changes are designed to deflect attention away from recent scandals involving the company, including a $3-billion fraud settlement in 2012 and ongoing bribery allegations in China. In 2014, drug and medical device companies will be required to report and disclose all payments to physicians and the information will be displayed in an online government database that you will be able to search. You can also search ProPublica's database to see the disclosed payments made to physicians in your state.

Celebrity Doctors and Bill Gates Linked to GlaxoSmithKline Fraud

By Dr. Mercola

One of the biggest news stories relating to health right now is the finalization of the biggest lawsuit yet by the American government against a pharmaceutical company.

On July 2, the British drug maker GlaxoSmithKline plead guilty to three counts of criminal misdemeanor and other civil liabilities relating to the prescription drugs Paxil, […]